Javascript must be enabled to continue!
Efficacy and Safety of Zolpidem for Focal Dystonia After Neurosurgical Treatments: A Retrospective Cohort Study
View through CrossRef
Although there are several reports of the significant efficacy of zolpidem for treating dystonia, zolpidem is still considered an anecdotal treatment. Here, we evaluated the efficacy and safety of zolpidem for treating residual dystonia in patients who previously received various neurosurgical treatments majorly including deep brain stimulation and radiofrequency ablation. We retrospectively reviewed medical records from January 2021 to September 2021 to identify patients with dystonia who had been prescribed zolpidem after undergoing neurosurgery. Twenty patients were enrolled in this study, including those with blepharospasm (two), tongue dystonia (four), mouth dystonia (one), spasmodic dysphonia (two), cervical dystonia (six), focal hand dystonia (three), hemidystonia (two), blepharospasm with cervical dystonia (one), and mouth dystonia with cervical dystonia (one). Single doses of zolpidem ranged between 2.5 and 10 mg, while daily dosages ranged from 10 to 30 mg. The zolpidem dose prescribed was 5–10 mg, with single and daily doses of 7 ± 2.9 and 14.5 ± 6.0 mg, respectively. With zolpidem administration, the participants' Burke-Fahn-Marsden Dystonia Rating Scale-Movement Scale score significantly improved from 8.1 ± 6.7 to 3.7 ± 2.5 (50.6% improvement, p < 0.0001). Improvements in arm dystonia, blepharospasm, and spasmodic dysphonia were observed using the Arm Dystonia Disability Scale, Jankovic Rating Scale, and Voice Handicap Index, respectively. No improvements were observed in cervical dystonia on the Toronto Western Spasmodic Torticollis Rating Scale. Drowsiness, including three cases each of mild and moderate drowsiness, was the most frequent adverse effect (30%), which persisted for 2–3 h. Transient amnesia and rapid eye movement sleep behavior disorder occurred in two patients and one patient, respectively. Although our findings suggest that zolpidem can be a valuable treatment option for patients with residual dystonia after neurosurgical treatments, the beneficial effects for cervical dystonia were limited.
Title: Efficacy and Safety of Zolpidem for Focal Dystonia After Neurosurgical Treatments: A Retrospective Cohort Study
Description:
Although there are several reports of the significant efficacy of zolpidem for treating dystonia, zolpidem is still considered an anecdotal treatment.
Here, we evaluated the efficacy and safety of zolpidem for treating residual dystonia in patients who previously received various neurosurgical treatments majorly including deep brain stimulation and radiofrequency ablation.
We retrospectively reviewed medical records from January 2021 to September 2021 to identify patients with dystonia who had been prescribed zolpidem after undergoing neurosurgery.
Twenty patients were enrolled in this study, including those with blepharospasm (two), tongue dystonia (four), mouth dystonia (one), spasmodic dysphonia (two), cervical dystonia (six), focal hand dystonia (three), hemidystonia (two), blepharospasm with cervical dystonia (one), and mouth dystonia with cervical dystonia (one).
Single doses of zolpidem ranged between 2.
5 and 10 mg, while daily dosages ranged from 10 to 30 mg.
The zolpidem dose prescribed was 5–10 mg, with single and daily doses of 7 ± 2.
9 and 14.
5 ± 6.
0 mg, respectively.
With zolpidem administration, the participants' Burke-Fahn-Marsden Dystonia Rating Scale-Movement Scale score significantly improved from 8.
1 ± 6.
7 to 3.
7 ± 2.
5 (50.
6% improvement, p < 0.
0001).
Improvements in arm dystonia, blepharospasm, and spasmodic dysphonia were observed using the Arm Dystonia Disability Scale, Jankovic Rating Scale, and Voice Handicap Index, respectively.
No improvements were observed in cervical dystonia on the Toronto Western Spasmodic Torticollis Rating Scale.
Drowsiness, including three cases each of mild and moderate drowsiness, was the most frequent adverse effect (30%), which persisted for 2–3 h.
Transient amnesia and rapid eye movement sleep behavior disorder occurred in two patients and one patient, respectively.
Although our findings suggest that zolpidem can be a valuable treatment option for patients with residual dystonia after neurosurgical treatments, the beneficial effects for cervical dystonia were limited.
Related Results
Clinical Presentation and Evolution of Isolated Focal and Segmental Dystonia in Adults – 20 Years’ Experience from a Botulinum Toxin Clinic
Clinical Presentation and Evolution of Isolated Focal and Segmental Dystonia in Adults – 20 Years’ Experience from a Botulinum Toxin Clinic
Background and Objectives:
Isolated dystonia generally occurs due to genetic causes, and the pattern and distribution may change over time. Botulinum toxin is t...
Rare Variant Burden in Known Dystonia Genes in Population Controls and Sporadic Dystonia Patients
Rare Variant Burden in Known Dystonia Genes in Population Controls and Sporadic Dystonia Patients
Abstract
Background
Rare mutations in genes associated with Mendelian forms of disease are a potential mechanism for sporadic d...
Zolpidem: a masked hero. A reply to ZORRO study
Zolpidem: a masked hero. A reply to ZORRO study
The use of zolpidem has been driven by the still-widespread false belief
among doctors that, since zolpidem is chemically not a benzodiazepine,
it cannot lead to addiction and tole...
Mechanism of action of the hypnotic zolpidem in vivo
Mechanism of action of the hypnotic zolpidem in vivo
Zolpidem is a widely used hypnotic agent acting at the GABAA receptor benzodiazepine site. On recombinant receptors, zolpidem displays a high affinity to α1‐GABAA receptors, an int...
Adult onset familial cervical dystonia: Report of a family including monozygotic twins
Adult onset familial cervical dystonia: Report of a family including monozygotic twins
AbstractWe report the first family with adult onset cervical dystonia in which monozygotic twins and multiple family members are affected. In this family, the disease exhibits an a...
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
Zolpidem-induced suicide attempt: a case report
Zolpidem-induced suicide attempt: a case report
Abstract
Zolpidem is a popular drug indicated for the short-term treatment of insomnia. Side effects are not uncommon with zolpidem. Herein we describe an Iranian 27-year...
Effect of Transcranial Direct Current Stimulation on Neurorehabilitation of Task-Specific Dystonia: A Double-Blind, Randomized Clinical Trial
Effect of Transcranial Direct Current Stimulation on Neurorehabilitation of Task-Specific Dystonia: A Double-Blind, Randomized Clinical Trial
Task-specific focal hand dystonia can disable affected individuals. Although neurorehabilitation techniques such as sensory motor retuning can result in complete recovery in some p...

